Cosan S.A. will end NYSE trading in its ADSs on September 18, 2026, through a voluntary delisting. Investors will still have access to the securities in the United States through Cosan’s Level I ADR program, which will continue supporting over-the-counter trading after the exchange exit.
Key Highlights
- The delisting follows material-fact notices dated August 14 and August 18, 2026.
- José Cezario Menezes de Barros Sobrinho signed as chief financial and Investor relations officer.
- Cosan is a publicly held company with CVM Code 19,836.
The ADS program will remain in place at Level I, allowing the securities to trade over the counter in the United States after the NYSE exit.
Voluntary Delisting Follows August Notices
Cosan (NYSE: CSAN) said the move follows material-fact notices issued on August 14 and August 18, 2026. The last trading day for its ADSs on the NYSE will be September 18, 2026. Cosan will keep its Level I ADR program after the exchange delisting, preserving OTC trading in the United States. José Cezario Menezes de Barros Sobrinho signed the notice as chief financial and investor relations officer.
Level I ADR Program Continues After NYSE Exit
The post-delisting arrangement allows Cosan ADSs to continue trading in the U.S. over-the-counter market. Cosan said it will continue informing shareholders and the wider market in line with applicable regulations. The company’s principal executive offices are in São Paulo, Brazil, at Av. Brigadeiro Faria Lima, 4100, 16th floor, São Paulo, SP 04538-132.
FAQs
Q: When will Cosan ADSs stop trading on the NYSE?
A: Cosan’s ADSs are due to have their final NYSE trading day on September 18, 2026, as part of the company’s voluntary delisting.
Q: What happens to Cosan ADSs after the NYSE delisting?
A: Cosan will maintain its Level I ADR program. Its ADSs will continue trading over the counter in the United States after the NYSE exit.
Q: Will Cosan ADSs remain available to U.S. investors?
A: Yes. Cosan’s Level I ADR program will remain active, allowing its ADSs to trade in the U.S. over-the-counter market after September 18, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.